PacBio Raises IPO Target to $230M, Enacts 1-for-2 Reverse Stock Split, Prices Shares

In an amended S-1 filing, the company also clarified its plans to provide methylation analysis as part of its PacBio RS platform.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.